The Food and Drug Administration approved Portola Pharmaceuticals Inc.'s (Nasdaq: PTLA) blood clot prevention drug Bevyxxa. Shares of the company surged $17.81 to close at $56.06.
FDA approves Portola's Bevyxxa
June 23, 2017 at 18:00 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.